Merluzzi, AP; Vogt, NM; Norton, D; Jonaitis, E; Clark, LR; Carlsson, CM; Johnson, SC; ... Bendlin, BB; + view all Merluzzi, AP; Vogt, NM; Norton, D; Jonaitis, E; Clark, LR; Carlsson, CM; Johnson, SC; Asthana, S; Blennow, K; Zetterberg, H; Bendlin, BB; - view fewer (2019) Differential effects of neurodegeneration biomarkers on subclinical cognitive decline. Alzheimer's and Dementia: Translational Research and Clinical Interventions , 5 pp. 129-138. 10.1016/j.trci.2019.02.004.

Preview

Text 1-s2.0-S2352873719300071-main.pdf - Published Version Download (784kB) | Preview

Abstract

Introduction: Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting subclinical cognitive decline. Methods: One hundred fifty cognitively unimpaired participants received a lumbar puncture for cerebrospinal fluid and at least two neuropsychological examinations (mean age at first visit = 59.3 ± 6.3 years; 67% female). Linear mixed effects models were used with cognitive composite scores as outcomes. Neurodegeneration interactions terms were the primary predictors of interest: age × NFL or age × neurogranin or age × t-tau. Models were compared using likelihood ratio tests. Results: Age × NFL accounted for a significant amount of variation in longitudinal change on preclinical Alzheimer's cognitive composite scores, memory composite scores, and learning scores, whereas age × neurogranin and age × t-tau did not. Discussion: These data suggest that NFL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers for neurodegeneration.

Download activity - last month

Export as JSONXMLCSV

Download activity - last 12 months

Export as CSVXMLJSON

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item